 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...1920212223242526272829...100101» |
- Kisqali (ribociclib) / Novartis
Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2 (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_450;
P3
12 mo (known poorer prognosis in 1L), demonstrated an OS HR consistent with that for the overall population. mOS surpassed that in the overall population (RIB, 69.2 mo vs PBO, 54.3 mo: an ?15-mo improvement with 1L RIB over PBO).
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
A randomised phase 2 trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_416;
P2
20% and/or high genomic risk (defined by gene signature), aiming to evaluate the clinical benefit and biological effects of HER3-DXd (with/without letrozole (LET)) as a neoadjuvant treatment. A total of 120 treatment na
- zanidatamab (ZW25) / Jazz
Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer (BC) (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_393;
Background Outcome of patients (pts) w/ stage I node neg HER2+ treated w/ wkly paclitaxel x 12 doses and trastuzumab x 1yr is excellent (10yr RFS 96%)...Three received tamoxifen and 3 letrozole...Conclusions Neoadjuvant zanidatamab for 3 months showed significant efficacy, (pCR/RCB-1 64%) w/ acceptable safety profile in pts w/ stage I node neg HER2+ BC. The trial is ongoing and has been modified to increase treatment duration to 5mths (10 cycles).
- Ibrance (palbociclib) / Pfizer
Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer. An analysis of the Unicancer Neopal phase II study. (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_392;
P2
Strikingly similar results were observed in the chemotherapy arm. Conclusions Neoadjuvant palbociclib activity in combination with letrozole does not seem to be influenced by the tumor's HER2 status (low versus zero).
- Ibrance (palbociclib) / Pfizer
Palbociclib in combination with letrozole in HR+/HER2- residual disease after standard neoadjuvant chemotherapy: primary results of the SOLTI1710 PROMETEO II window of opportunity trial (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_391;
P1
Conclusions In chemo-resistant residual disease in pts with HR+/HER2- BC, palbociclib induce a potent anti-proliferative effect. A direct relationship between immune infiltration and anti-proliferative response exists, where immune infiltration is increased in residual tumors with CCCA.
- letrozole / Generic mfg., tamoxifen / Generic mfg.
SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): a multicenter, prospective study (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_303;
P3
Genotype-based groups were negatively associated with skeletal events (p=0.025); even after adjusting for age, BMI, smoke (p=0.028). Conclusions SNPs of CYP19 predict metastasis and skeletal events in patients receiving AIs, opening the opportunity to individualize therapy in ER+ BC survivors.
- |||||||||| culmerciclib (TQB3616) / Sino Biopharm
New P3 trial: Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer (clinicaltrials.gov) - Mar 22, 2023
P3, N=1946, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | FDA event, Journal: Computational screening of FDA-approved drugs to identify potential aromatase receptor inhibitors for polycystic ovary syndrome. (Pubmed Central) - Mar 21, 2023
Finally, acetaminophen, alendronate, ascorbic acid, aspirin, glutamine, hydralazine, mesalazine and pseudoephedrine drugs showed the best results in interaction with aromatase receptor based on computational studies. These drugs can be introduced as an alternative to letrozole for treating PCOS.Communicated by Ramaswamy H. Sarma.
- | letrozole / Generic mfg.
Preclinical, Journal: Hormonal and genotoxic estrogen-androgen carcinogenesis in the NBL rat prostate: A role for aromatase. (Pubmed Central) - Mar 21, 2023
These and previous data indicate that androgen receptor-mediated action, estrogen receptor mediation, and estrogen genotoxicity are all required and sufficient for hormonal carcinogenesis in the NBL rat prostate. Interference with the estrogen genotoxicity is a potential approach to prostate cancer chemoprevention.
- | metformin / Generic mfg., letrozole / Generic mfg., spironolactone / Generic mfg.
Journal: Polycystic Ovary Syndrome: Common Questions and Answers. (Pubmed Central) - Mar 20, 2023
Metformin added to lifestyle management is first-line therapy for patients with metabolic complications such as insulin resistance. Patients with PCOS are at increased risk of depression and obstructive sleep apnea, and screening is recommended.
- |||||||||| camizestrant (AZD9833) / AstraZeneca
New P3 trial: CAMBRIA-1: A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (clinicaltrials.gov) - Mar 20, 2023
P3, N=4300, Not yet recruiting, Sponsor: AstraZeneca
- | Enrollment open: Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer (clinicaltrials.gov) - Mar 20, 2023
P2, N=236, Recruiting, Sponsor: Shengjing Hospital
Patients with PCOS are at increased risk of depression and obstructive sleep apnea, and screening is recommended. Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Journal: A triple-blind randomized controlled trial comparing combined letrozole and clomiphene versus only letrozole for ovulation induction in PCOS women. (Pubmed Central) - Mar 16, 2023
Not yet recruiting --> Recruiting Combined treatment of letrozole and clomiphene may be considered as one of the first-line ovulation induction agents for infertile women with PCOS because of its affordability and better safety profile.
- | letrozole / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant Endocrine Therapy: A Potential Way to Make Cold Hormone Receptor-Rich Breast Cancer Hot. (Pubmed Central) - Mar 16, 2023
Neoadjuvant endocrine therapy showed a promising way to convert the immunologically "cold" HR+ BCs into "hot" tumors. This study provides new insights into the application of immunotherapy for HR+ BCs, especially those who respond to endocrine therapy.
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Metastases: ABIGAIL: ABemaciclib, ET (clinicaltrials.gov) - Mar 16, 2023
P2, N=160, Recruiting, Sponsor: MedSIR
This study provides new insights into the application of immunotherapy for HR+ BCs, especially those who respond to endocrine therapy. Trial primary completion date: Feb 2023 --> Sep 2023
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Enrollment change: ORACLE-RIPA: A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC (clinicaltrials.gov) - Mar 16, 2023
P2, N=60, Recruiting, Sponsor: National Taiwan University Hospital
Trial primary completion date: Feb 2023 --> Sep 2023 N=20 --> 60
- | Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Mar 16, 2023
P2, N=47, Recruiting, Sponsor: City of Hope Medical Center
N=20 --> 60 Suspended --> Recruiting
- | Journal, Adherence: Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer. (Pubmed Central) - Mar 15, 2023
Suspended --> Recruiting Patients who initiated with tamoxifen had a steeper decrease in adherence over the 5
- | letrozole / Generic mfg.
Journal: Effects of letrozole combined with ethinylestradiol and cyproterone acetate tablets on serum sex hormones and lipid metabolism in patients with polycystic ovary syndrome. (Pubmed Central) - Mar 15, 2023
Patients who initiated with tamoxifen had a steeper decrease in adherence over the 5 Letrozole combined with ethinylestradiol and cyproterone acetate tablets can enhance the treatment efficiency of PCOS and improve serum sex hormones and lipid metabolism in PCOS patients.
- | nitroprusside / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: The regulatory effect of sex steroids on the RhoA/ROCK pathway in the rat distal vagina. (Pubmed Central) - Mar 14, 2023
Letrozole combined with ethinylestradiol and cyproterone acetate tablets can enhance the treatment efficiency of PCOS and improve serum sex hormones and lipid metabolism in PCOS patients. Androgens, by inhibiting the RhoA/ROCK pathway, could positively contribute to vaginal smooth muscle relaxation, favoring sexual intercourse.
- | metformin / Generic mfg., letrozole / Generic mfg.
Journal: Ameliorative effect of sesame oil on experimentally induced polycystic ovary syndrome: A cross-link between XBP-1/PPAR-1, regulatory proteins for lipogenesis/steroids. (Pubmed Central) - Mar 14, 2023
SO proved to have a marvelous effect on the metabolic and endocrine derangements in the PCOS rat model. We hoped to provide a valuable alternative treatment for PCOS patients to avoid the side effects of metformin and to help PCOS patients for whom metformin is contraindicated.
- Ibrance (palbociclib) / Pfizer
Weight loss intervention triggered gut microbiota modulation can positively impact obesity associated endocrine therapy resistance (Section 5; Poster Board #27) - Mar 14, 2023 - Abstract #AACR2023AACR_8901;
Direct interaction between breast cancer cells and WAT rendered them resistant to multiple drugs. Metabolites produced by weight-loss-associated bacterium F. prausnitzii reversed adiposity-induced multi-drug resistance, hence, can potentially have therapeutic benefits in obese breast cancer patients.
- Kisqali (ribociclib) / Novartis
Cancer cells subvert fibroblast function to promote a growth factor enriched tumor microenvironment in endocrine therapy resistant ER+ breast cancer (Valencia BC - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_7834;
In response to growth factor enrichment, cancer cells of ET-resistant tumors showed activation of MAPK signal transduction and downstream transcription factors promoting proliferation including FOS, JUN and TRIB1. These results indicate that ET resistance emerges in patient tumors when cancer cells subvert fibroblast function to promote a growth factor enriched tumor microenvironment permitting estrogen independent cancer proliferation.
- gedatolisib (PF-05212384) / Celcuity
Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on gynecological cancer models regardless of their PI3K pathway mutational status (Section 15; Poster Board #6) - Mar 14, 2023 - Abstract #AACR2023AACR_7329;
Gedatolisib as a single agent and in combination with other therapies has previously reported promising preliminary clinical efficacy and safety in various solid tumor types, including EC. In summary, nonclinical and preliminary clinical data supports the development of gedatolisib in combination with hormonal therapy for treatment of patients with EC.
- letrozole / Generic mfg.
Treatment of aromatase inhibitor-resistant cells with polyisoprenylated cysteinyl amide inhibitors stimulates the mitogen-activated protein kinase pathway enzymes, impedes cell proliferation and causes cell death (Section 18; Poster Board #22) - Mar 14, 2023 - Abstract #AACR2023AACR_7203;
Here, long-term letrozole-treated (LTLT-Ca) breast cancer cells were used to evaluate polyisoprenylated cysteinyl amide inhibitors (PCAIs) as potential alternative therapies for the treatment of aromatase inhibitor-resistant breast cancer...The results reveal the ability of the PCAIs to effectively cause a negative impact on several cancer hallmarks suggesting their potency as anticancer agents. These findings also support a potential role for PCAIs
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Which are the clinicopathological characteristics useful to define the metastatic breast cancer patients that will respond to CDK4/6 inhibitors and hormone therapy? An Italian real-world experience (Section 37; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_6923;
177 mBC patients 66 of whom were treated with CD4/6 inhibitors plus letrozole and 111 treated with CDK4/6 inhibitors and fulvestrant were enrolled in the study...Finally, the neutropenia status was associated with a more than double risk of progression/death with respect to patients without neutropenia (HR=2.311; p=0.025). Given that we identified a set of factors associated with the probability to develop neutropenia and considering that neutropenia itself is associated with an increased risk of progression, these baseline characteristics should be taken into account in order to reduce the occurrence of both neutropenia and disease progression.
- Kisqali (ribociclib) / Novartis
Cancer cell communication with macrophages prevents T cell activation during emergence of cell cycle therapy resistance (Section 33; Poster Board #16) - Mar 14, 2023 - Abstract #AACR2023AACR_5763;
These results indicate that cancer communications promoting an immune-cold TME predispose tumors to develop CDK4/6 cell cycle inhibitor resistance, and that the beneficial effects of blocking cancer cell proliferation must be balanced against their inhibitory effect on immune cell division and activation. An optimal treatment strategy will require coupling the prevention of cancer division with activation of an effective cytotoxic T-cell response.
- letrozole / Generic mfg.
Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy (Room W311 E-H - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_5553;
We investigated the tumor microenvironment (TME) in estrogen receptor positive (ER+) primary breast cancers from stage I-III patients treated with estrogen deprivation (ED, induced with letrozole) for 10-21 days...In summary, our study shows that activated anti-tumor immune cells are enriched in the TME of ER+ breast tumors resistant to estrogen deprivation, whereas ED-sensitive tumors show a more immunosuppressed or immune cold milieu. These data suggest a potential causal link between antiestrogen treatment and modulation of antitumor immunity in ER+ breast cancers.
- Individualizing treatment using patient derived organoids, BH3 profiling and microfluidics: A proof of concept in a patient with low-grade serous ovarian carcinoma (Section 6; Poster Board #14) - Mar 14, 2023 - Abstract #AACR2023AACR_2977;
Neither carboplatin and paclitaxel alone, nor in combination, elicited a significant change in viability. This observation was consistent with the patient
- letrozole / Generic mfg.
Novel therapeutic combination targets the growth of letrozole resistant breast cancer through decreased cyclin B1 (Section 15; Poster Board #1) - Mar 14, 2023 - Abstract #AACR2023AACR_2506;
This work was supported by NIH grant #1SC1GM126617 and U54MD007582. Interestingly, while there there was no effect on protein expression in the AC-1 cells, glyceollin
- | Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Journal, HEOR, Combination therapy, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. (Pubmed Central) - Mar 13, 2023
P3
This analysis with updated data assessed the cost-effectiveness of ribociclib versus palbociclib, both in combination with letrozole, in the setting of 1L therapy of postmenopausal women with HR+/HER2- ABC, from a United Kingdom (UK) National Health Service perspective. At a
- | letrozole / Generic mfg.
New trial: Combined Chromium With Letrozole Versus Letrozole Only in Induction of Ovulation in Patients With Polycystic Ovary Syndrome (clinicaltrials.gov) - Mar 13, 2023
P=N/A, N=90, Completed, Sponsor: Cairo University
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
New P2 trial: ORACLE-RIPA: A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC (clinicaltrials.gov) - Mar 13, 2023
P2, N=20, Recruiting, Sponsor: National Taiwan University Hospital
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Trial primary completion date, Combination therapy, Metastases: GOG-3039: Abemaciclib and Letrozole to Treat Endometrial Cancer (clinicaltrials.gov) - Mar 13, 2023
P2, N=50, Recruiting, Sponsor: Gynecologic Oncology Group
At a Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2023 --> Dec 2023
- |||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Metastases: INGE-B: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (clinicaltrials.gov) - Mar 13, 2023
P2, N=388, Completed, Sponsor: iOMEDICO AG
Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2023 --> Dec 2023 Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Feb 2023
- | Journal, Metastases: Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients. (Pubmed Central) - Mar 10, 2023
Moreover, the expression of miR-199a and miR-663b was significantly correlated with the response to treatment, in which the expression of miR-199a was higher in the poor-response group (P=0.049), while the higher expression of miR-663b was seen in the good-response group (P=0.009). These findings state that the high plasma level of miR-199a and the low plasma level of miR-663b may be related to chemoresistance in patients with metastatic breast cancer.
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment change, Trial completion date: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Mar 10, 2023
P3, N=5083, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
These findings state that the high plasma level of miR-199a and the low plasma level of miR-663b may be related to chemoresistance in patients with metastatic breast cancer. N=10000 --> 5083 | Trial completion date: Feb 2023 --> Mar 2024
- ||| tagtociclib (PF-07104091) / Pfizer
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: PF-07104091 as a Single Agent and in Combination Therapy (clinicaltrials.gov) - Mar 10, 2023
P1/2, N=320, Recruiting, Sponsor: Pfizer
N=10000 --> 5083 | Trial completion date: Feb 2023 --> Mar 2024 Phase classification: P2 --> P1/2 | N=240 --> 320 | Trial completion date: Nov 2027 --> Jan 2026 | Trial primary completion date: Nov 2026 --> Jan 2025
- | letrozole / Generic mfg.
Preclinical, Journal: Comparative Evaluation of Aldose Reductase Inhibition in Polycystic Ovarian Syndrome-Induced Rats. (Pubmed Central) - Mar 9, 2023
Phase classification: P2 --> P1/2 | N=240 --> 320 | Trial completion date: Nov 2027 --> Jan 2026 | Trial primary completion date: Nov 2026 --> Jan 2025 PCOS is induced either by administering letrozole or by feeding high-fat diet for 90
- Analyzing the Effect of Estrogen Deprivation Therapy Type on Sleep in Breast Cancer Survivors () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1144;
Data suggest that pharmacotherapy type may impact both the subjective and objective BCS experience of sleep during EDT. Thus, this study
- || PF-07248144 / Pfizer
Trial completion date, Trial primary completion date, Metastases: C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 8, 2023
P1, N=186, Recruiting, Sponsor: Pfizer
Thus, this study Trial completion date: Sep 2027 --> Nov 2026 | Trial primary completion date: Apr 2026 --> May 2025
- | letrozole / Generic mfg.
Journal: Single dose letrozole and misoprostol for termination of pregnancy through 63 days' gestation: A pilot study. (Pubmed Central) - Mar 7, 2023
Trial completion date: Sep 2027 --> Nov 2026 | Trial primary completion date: Apr 2026 --> May 2025 A single dose of letrozole does not appear to be an effective adjunct to misoprostol for medication abortion.
- | letrozole / Generic mfg.
Journal: Optimal lead follicle size in letrozole human menopausal gonadotrophin intrauterine insemination cycles with and without spontaneous LH surge. (Pubmed Central) - Mar 7, 2023
The optimal lead follicle size was between 16.1 and 18.0 mm in HCG-triggered letrozole HMG IUI cycles. If the lead follicle size is relatively small (14.1-18.0 mm) when a spontaneous LH surge occurs, there is no need to cancel the IUI cycle.
- ||| Review, Journal, Adverse events: Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). (Pubmed Central) - Mar 7, 2023
While unable to imply incidence rates from our data due to the nature of the FAERS database, our findings provide further description of the various medications associated with ONJ and elucidate patient demographics associated with the ADR. Additionally, our study identifies cases of several newly described drugs and drug classes that have not been previously described in literature.
- || Biomarker, Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Biomarker-driven therapy in endometrial cancer. (Pubmed Central) - Mar 7, 2023
Other treatment regimens being evaluated in NSMP/CNL are hormonal combinations with cyclin-dependent kinase 4/6 inhibitors and letrozole...Treatment de-escalation is being evaluated in POLEmut cases given its favorable prognosis with or without adjuvant therapy. Molecular subtyping has important prognostic and therapeutic implications, and should guide patient management and clinical trial design in endometrial cancer, which is a molecularly driven disease.
- ||| Journal, Adverse events: A preliminary study to identify existing drugs for potential repurposing in breast cancer based on side effect profile. (Pubmed Central) - Mar 7, 2023
PROMISCUOUS database was used to construct a group of drugs that share maximum side effects with letrozole. From the in vitro results, ropinirole and risperidone showed good anti-cancer activity of IC with 40.85
- | Herceptin (trastuzumab) / Roche
Trial primary completion date: ARETTA: Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer (clinicaltrials.gov) - Mar 7, 2023
P2, N=60, Recruiting, Sponsor: University of Chicago
From the in vitro results, ropinirole and risperidone showed good anti-cancer activity of IC with 40.85 Trial primary completion date: Sep 2022 --> Sep 2023
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: PLEASURABLE: Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (clinicaltrials.gov) - Mar 7, 2023
P1/2, N=59, Active, not recruiting, Sponsor: Fudan University
Trial primary completion date: Sep 2022 --> Sep 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Jun 2023
- | Orserdu (elacestrant) / Menarini
Journal, Metastases: Elacestrant (Orserdu) for advanced or metastatic breast cancer. (Pubmed Central) - Mar 7, 2023
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Jun 2023 No abstract available